He is also a BOT holder, and I will propose a comparison with BOT and DXB.
BOT heading into Phase 2 trial for Acne last year was capped at 250M MC or so.
DXB capped at 150M MC heading into Phase 2 trials for its Kidney Disease. Currently capped at 50-60M MC after that trial flopped.
IHL heading into Phase 2 trial for Obstructive Sleep Apnea currently at 90-96M MC.
Downside is always there if clinical trial results dont go as expected, but comparatively the risk/reward that is present with IHL is still enormously good. If you dont like these odds then you probably wont like biotech.
IHL is currently cheap as chips for what it is undertaking. Which means far more multiples in upside and less downside...
IHL Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
